Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Precision lead placement could boost heart failure device success

NCT ID NCT03280862

First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 37 times

Summary

This study tested whether placing the left ventricle lead of a cardiac resynchronization therapy (CRT) device at the heart's latest electrical activation spot improves outcomes. It included 1,000 heart failure patients with bundle branch block. The goal was to see if this targeted approach reduces death or unplanned heart failure hospitalizations compared to standard lead placement.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, 9000, Denmark

  • Aarhus University Hospital

    Aarhus, 8200, Denmark

  • Gentofte University Hospital

    Gentofte Municipality, 2900, Denmark

  • Odense University Hospital

    Odense, 5000, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cardiac resynchronization therapy (CRT) device implantation

What this could lead to

If successful, this approach could reduce deaths and hospitalizations for heart failure patients by improving how the device is placed.

What could go wrong

The trial is completed but results are not yet widely confirmed. Targeted placement may increase procedure time, infection risk, or radiation exposure, and might not benefit all patients.

Conditions

The condition(s) this trial relates to.

bundle branch block, familial isolated complete right heart failure progressive familial heart block, type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.